Cited by 75Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesNicotinic Acetylcholine Receptors Study

A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation

Open access
McKee, Sherry A, Potenza, Marc N, Kober, Hedy, Sofuoglu, Mehmet, Arnsten, Amy FT, Picciotto, Marina R, Weinberger, Andrea H, Ashare, Rebecca +1 more·2015·Journal of Psychopharmacology

Abstract

Stress and prefrontal cognitive dysfunction have key roles in driving smoking; however, there are no therapeutics for smoking cessation that attenuate the effects of stress on smoking and enhance cognition. Central noradrenergic pathways are involved in stress-induced reinstatement to nicotine and in the prefrontal executive control of adaptive behaviors. We used a novel translational approach employing a validated laboratory analogue of stress-precipitated smoking, functional magnetic resonance imaging (fMRI), and a proof-of-concept treatment period to evaluate whether the noradrenergic α2a agonist guanfacine (3 mg/day) versus placebo (0 mg/day) reduced stress-precipitated smoking in the laboratory, altered cortico-striatal activation during the Stroop cognitive-control task, and reduced smoking following a quit attempt. In nicotine-deprived smokers ( n=33), stress versus a neutral condition significantly decreased the latency to smoke, and increased tobacco craving, ad-libitum smoking, and systolic blood pressure in placebo-treated subjects, and these effects were absent or reduced in guanfacine-treated subjects. Following stress, placebo-treated subjects demonstrated decreased cortisol levels whereas guanfacine-treated subjects demonstrated increased levels. Guanfacine, compared with placebo, altered prefrontal activity during a cognitive-control task, and reduced cigarette use but did not increase complete abstinence during treatment. These preliminary laboratory, neuroimaging, and clinical outcome data were consistent and complementary and support further development of guanfacine for smoking cessation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881114562091

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • McKee et al. (2015) found guanfacine reduced stress-induced smoking in the lab and helped people quit smoking at home.

    “McKee et al. (2015) found that guanfacine reduced stress-induced smoking in the lab, and helped people quit smoking at home.”

    From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as McKee et al. (2015)

    The Discussion (page not supplied) reports that guanfacine reduced stress-precipitated smoking lapse in the laboratory and reduced cigarette use during a brief treatment period. It also says that an effect on complete abstinence was not demonstrated, so the claim that it helped people quit smoking at home overstates the finding. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • Guanfacine improves PFC functions and reduces cravings in subjects with stress-induced substance abuse.

    “Guanfacine is now in widespread use for the treatment of PFC disorders on the basis of research in animals, and it has been shown to improve PFC functions and reduce cravings in subjects with stress-induced substance abuse112,113.”

    From Stress weakens prefrontal networks: molecular insults to higher cognition (2015) · cites this paper as [112]

    The Discussion reports reduced stress-related tobacco craving and increased prefrontal activity during a cognitive-control task in smokers receiving guanfacine. It interprets the neural findings as suggesting improved executive-control function, but reports no between-group difference in Stroop performance. The claim extends these findings in smokers to people with stress-induced substance abuse more broadly. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Engberg G Eriksson E 1991 Effects of alpha-2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in EEDQ-treated rats Naunyn-Schmiedeberg Arch Pharmacol 343 472 477 1652697
  2. First MB Spitzer RL Gibbon M Williams JB 1996 Structured Clinical Interview for DSM-IV Axis I Disorders--Patient Edition Biometrics Research Department, New York State Psychiatric Institution New York
  3. Jentsch JD Wise A Katz Z Roth RH 1998 Alpha-noradrenergic receptor modulation of the phencyclidine- and delta9-tetrahydrocannabinol-induced increases in dopamine utilization in rat prefrontal cortex Synapse 28 21 26 9414014

Cited by

Sorted by citations

Authors
McKee, S. A., Potenza, M. N., Kober, H., Sofuoglu, M., Arnsten, A. F., Picciotto, M. R., Weinberger, A. H., Ashare, R., & Sinha, R.
Affiliations
  • Yale Cancer Center (US)
  • Yale University (US)
  • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
  • University of Pennsylvania (US)
Venue
Journal of Psychopharmacology
Published
2014-12-16
Volume
29
Issue
3
Pages
300-311
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2018919329
Cited by
75
References
68
Citations by year
2026: 2 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 8 · 2019: 11 · 2018: 11 · 2017: 9 · 2016: 8 · 2015: 10
FWCI
6.00
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (UL1TR000142)
  • National Institute on Alcohol Abuse and Alcoholism (RL1AA017539)
  • National Institute on Drug Abuse (R21DA033597, R01DA014241, RL1DA024857, P20DA027844, PL1DA024860, PL1DA024859, P50DA033945, K12DA000167, R37DA014241, R01DA035001)
  • National Institute of Dental and Craniofacial Research (UL1DE019586)
  • National Center for Research Resources (UL1RR024139)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
guanfacine, smoking cessation, stress reactivity, nicotine craving, Stroop task, nicotine deprivation, cortisol, blood pressure
MeSH terms
Smoking Prevention, Adult, Blood Pressure, Cognition, Double-Blind Method, Humans, Hydrocortisone, Magnetic Resonance Imaging, Male, Middle Aged, Smoking, Stress, Psychological, Guanfacine, Smoking Cessation, Prefrontal Cortex, Young Adult, Adrenergic alpha-2 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review